Cargando…

The Effect of Sodium Glucose Cotransporter 2 Inhibitors From a Human Genetic Perspective

Detalles Bibliográficos
Autores principales:	Liu, Xing-zi, Zhang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017288/ https://www.ncbi.nlm.nih.gov/pubmed/33815487 http://dx.doi.org/10.3389/fgene.2021.658012

Ejemplares similares

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
por: John, Mathew, et al.
Publicado: (2016)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
por: Maccari, Rosanna, et al.
Publicado: (2022)

Erratum: Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
por: Chen, Lu, et al.
Publicado: (2020)

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
por: Yanai, Hidekatsu, et al.
Publicado: (2016)

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
por: Wu, Jinchun, et al.
Publicado: (2022)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
por: Seo, Ji A
Publicado: (2019)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
por: Fonseca-Correa, Jorge I., et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
por: Li, Hang-Long, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
por: Saha, Arunava, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Genetic and Biological Effects of SLC12A3, a Sodium-Chloride Cotransporter, in Gitelman Syndrome and Diabetic Kidney Disease
por: Li, Nan, et al.
Publicado: (2022)

Increasing Sodium-Glucose Cotransporter 2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway
por: Nishi, Laura, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6eb492ta9d2nlfuo5vro12b924